Stage 1 Mesothelioma: Symptoms, Treatment & Outlook

Stage 1 pleural mesothelioma is the earliest stage in the current formal staging system for diffuse pleural mesothelioma. At this stage, the tumor remains limited to the pleura on one side of the chest, has not spread to regional lymph nodes, and has not metastasized to distant parts of the body.

Under the current American Joint Committee on Cancer (AJCC) Version 9 TNM staging system, Stage 1 pleural mesothelioma is defined as T1 N0 M0.

For the clinical T1 category, the tumor is limited to the ipsilateral pleura, the sum of pleural thickness measurements (Psum) is 12 mm or less, and there is no qualifying fissural involvement. There is also no regional lymph-node involvement (N0) and no distant metastasis (M0).

Importantly, AJCC Version 9 no longer divides Stage 1 pleural mesothelioma into Stage IA and Stage IB. Patients may still encounter those terms in older articles or records based on previous staging systems, but they should not be presented as current Version 9 Stage 1 categories.

Stage 1 disease may provide more treatment options compared to later-stage mesothelioma; however, treatment decisions are not based solely on stage. Other critical factors include histologic subtype, resectability, cardiopulmonary fitness, overall health, and patient preferences.

Stage 1 Mesothelioma at a Glance

What Does Stage 1 Mesothelioma Mean?

Cancer staging describes the anatomical extent of disease at the time it is evaluated. For pleural mesothelioma, doctors use the TNM system:

• T — Tumor: the extent and measurable characteristics of the primary pleural tumor.
• N — Nodes: whether regional lymph nodes contain cancer.
• M — Metastasis: whether cancer has spread to distant parts of the body.

Stage 1 is assigned when all three components meet the following criteria:

T1

The tumor is limited to the pleura on the same side of the chest as the primary disease. For clinical T1 (cT1) under AJCC Version 9: Psum is 12 mm or less; and there is no qualifying involvement of the interlobar fissure, with Fmax 5 mm or less.

N0

There is no identified spread to regional lymph nodes.

M0

There is no identified distant metastatic disease.

Together: T1 + N0 + M0 = Stage I. See our mesothelioma stages overview for how Stage 1 relates to the full AJCC staging system.

Stage 1A and Stage 1B: Are They Still Used?

Not in the current AJCC Version 9 staging system for diffuse pleural mesothelioma.

Older staging systems divided early pleural mesothelioma into categories such as Stage IA and Stage IB. That distinction should not be carried forward into current Version 9 descriptions. Under Version 9, the current stage grouping is simply Stage I — T1 N0 M0.

This distinction is important because individuals seeking information online may encounter content based on previous AJCC editions. When comparing staging information, it is essential to verify the version of the staging system being referenced.

What Is Psum?

Psum is one of the major changes introduced into the clinical T classification of pleural mesothelioma. Pleural mesothelioma does not always form a single round mass that can be measured in the same way as many other solid tumors — it often grows along pleural surfaces. AJCC Version 9 therefore incorporates measurements of pleural thickness on CT imaging.

Psum represents the sum of three measurements of maximum pleural thickness obtained from the upper chest, middle chest, and lower chest. These measurements are taken along the chest wall or mediastinal pleural surfaces. The three maximum measurements are added together:

Psum = pmax1 + pmax2 + pmax3

For clinical T1 disease: Psum ≤12 mm.

What Is Fmax?

Fmax describes the maximum thickness of pleural tumor involving the interlobar fissure. It is assessed on imaging, typically using sagittal CT images.

For clinical T1: Fmax ≤5 mm. More substantial fissural involvement can contribute to classification as T2 rather than T1.

The introduction of Psum and Fmax is important because it makes the Version 9 clinical T classification more quantitative than previous editions.

Stage 1 vs Stage 2 Mesothelioma

The distinction between Stage 1 and Stage 2 is not simply that the tumor is “slightly larger.” Stage 2 includes different combinations of tumor extent and lymph-node involvement.

A person with a relatively limited T1 tumor who has ipsilateral regional lymph-node involvement can therefore be classified as Stage 2. This illustrates why stage cannot be determined solely by tumor thickness. See our Stage 2 mesothelioma guide for more detail.

What Are the Symptoms of Stage 1 Mesothelioma?

Stage 1 mesothelioma does not have a unique set of symptoms. Some people can have relatively subtle symptoms at an early stage, while others may already experience significant discomfort.

Possible symptoms include:

• shortness of breath;
• chest pain or pressure;
• persistent cough;
• fatigue;
• reduced exercise tolerance;
• pleural effusion, or fluid around the lung;
• unexplained weight loss;
• decreased appetite.

These symptoms are nonspecific and may also occur in various other respiratory or medical conditions. Symptoms alone cannot reliably indicate the cancer stage. A person with Stage 1 disease can have substantial symptoms because of a pleural effusion, while another person with more extensive disease might initially report fewer symptoms. Staging requires imaging, pathology, and clinical assessment. Our symptoms guide covers the broader range of possible signs.

How Is Stage 1 Mesothelioma Diagnosed?

Diagnosing Stage 1 pleural mesothelioma requires answering two separate questions: is the disease truly mesothelioma, and how far has it spread? A staging classification should not substitute for a definitive pathologic diagnosis. Our diagnosis guide and tests and biopsy guide cover this process in more detail.

Initial Imaging

Chest imaging may first identify abnormalities such as pleural thickening, pleural nodularity, pleural effusion, pleural masses, or loss of normal pleural contours. Contrast-enhanced CT is particularly important for evaluating pleural tumor distribution and for clinical staging. Under Version 9, CT also plays a direct role in assigning the clinical T category because Psum and Fmax are imaging-based measurements. Our imaging tests guide covers CT, PET, and MRI in more detail.

Pleural Fluid Evaluation

If a patient presents with a symptomatic pleural effusion, thoracentesis may be performed both to relieve symptoms and to obtain fluid for cytologic evaluation. However, pleural-fluid cytology alone may not provide enough information to establish or subtype mesothelioma reliably in every patient. When antineoplastic treatment is planned, adequate tissue sampling is particularly important.

Biopsy and Pathology

A tissue biopsy is generally required for a definitive diagnosis. For patients in whom active cancer treatment is being considered, current ASCO guidance strongly supports obtaining adequate tissue, often through thoracoscopic biopsy when appropriate.

A tissue specimen allows the pathologist to confirm malignant mesothelioma, distinguish it from metastatic carcinoma and other pleural tumors, determine histologic subtype, perform appropriate immunohistochemical testing, and assess additional pathologic features that can influence treatment planning. The principal histologic patterns include epithelioid, biphasic, and sarcomatoid disease. Histology is especially important when considering surgery.

Epithelioid Mesothelioma

Epithelioid mesothelioma is the most common histologic subtype and is generally associated with a more favorable prognosis than sarcomatoid or biphasic disease. Histologic subtype also influences treatment selection — for example, current ASCO guidance on maximal surgical cytoreduction specifically emphasizes highly selected patients with favorable features, including epithelioid histology.

Imaging for Staging

The purpose of staging imaging is not simply to confirm that a pleural mass exists. Doctors need to evaluate total pleural tumor extent, fissural involvement, neighboring structures, regional lymph nodes, the opposite chest, and potential distant metastatic disease. Depending on the clinical situation, evaluation can include CT and additional imaging such as PET/CT or MRI. No individual imaging modality provides complete diagnostic accuracy, and findings that would substantially change treatment may sometimes require further evaluation or tissue confirmation.

Lymph-Node Assessment

Stage 1 requires N0 — no regional lymph-node involvement has been identified. Accurate nodal assessment is particularly important when aggressive local treatment or surgery is being considered. A tumor that remains T1 but is found to involve N1 regional lymph nodes would no longer be Stage 1 under Version 9; it would instead meet a Stage 2 grouping, T1 N1 M0. This illustrates why a patient should not be described as having Stage 1 disease based only on the appearance of the primary pleural tumor.

Clinical Stage vs Pathologic Stage

Pleural mesothelioma can have both a clinical and, when surgery is performed, a pathologic stage. Clinical staging is based on information available before definitive surgery, including imaging, biopsy, physical and clinical findings, and assessment of lymph nodes and distant disease; Version 9 clinical T staging uses quantitative CT measurements such as Psum and Fmax. If surgery is performed, tissue removed during the operation can provide additional information and produce a pathologic stage. Clinical and pathologic stages do not always match, since surgery can reveal disease that was not apparent on preoperative imaging.

Is Stage 1 Mesothelioma Resectable?

Many Stage 1 pleural mesotheliomas may appear anatomically resectable. However, Stage 1 does not automatically mean surgery should be performed. This distinction is crucial for appropriate treatment planning.

Resectability asks whether maximal removal of visible tumor can reasonably be achieved. Treatment suitability asks a broader question: would major surgery provide a favorable balance of potential benefit and risk for this particular patient?

Current ASCO guidance states that surgical cytoreduction should not be offered routinely to all patients based solely on anatomical resectability. Instead, it should be reserved for highly selected patients with favorable clinical characteristics after comprehensive staging and multidisciplinary review.

Surgery for Stage 1 Mesothelioma

Surgical cytoreduction may be considered for selected patients with early pleural mesothelioma. Factors supporting consideration of surgery can include early clinical T category, N0 disease, epithelioid histology, adequate cardiopulmonary reserve, good functional status, absence of significant contraindications, and the ability to undergo multimodality treatment.

ASCO’s current guidance particularly identifies clinical T1–T3 N0 epithelioid tumors as the favorable group in which maximal surgical cytoreduction may be considered. This makes a patient with Stage 1 T1 N0 disease anatomically relevant for surgical evaluation, but histology and overall fitness remain essential.

Pleurectomy/Decortication

Pleurectomy/decortication is a lung-sparing surgical approach intended to remove visible pleural tumor while preserving the underlying lung. The exact extent of surgery can vary depending on tumor involvement and institutional practice. Mesothelioma surgery is technically complex and should be evaluated at centers with specific experience in pleural mesothelioma.

Extrapleural Pneumonectomy

Extrapleural pneumonectomy is a more extensive procedure involving removal of the affected lung together with additional involved pleural and adjacent tissues. Because of its greater physiologic impact and potential morbidity, it is not an operation that should be presented as routine therapy for Stage 1 disease. Modern treatment selection increasingly emphasizes careful patient selection and lung-sparing approaches when maximal surgical cytoreduction is undertaken, and lung preservation is feasible.

When Surgery Is Used, It Is Usually Part of a Broader Strategy

Even when all visible tumor is removed, microscopic mesothelioma cells may remain. Therefore, surgery should not be regarded as a guarantee of complete disease eradication. Current ASCO guidance states that maximal surgical cytoreduction alone is generally insufficient and that additional antineoplastic therapy should be incorporated when appropriate. Treatment can therefore involve combinations or sequences of surgery, systemic therapy, and radiation therapy in selected situations. The specific combination and sequence of treatments may differ among patients and specialized mesothelioma centers. Our treatment guide covers these approaches across all stages.

Chemotherapy

Platinum-based chemotherapy with pemetrexed remains an established systemic treatment for pleural mesothelioma. The platinum component is commonly cisplatin or carboplatin.

In patients undergoing a surgery-based multimodality strategy, systemic chemotherapy can be given before or after surgery depending on the treatment plan. Current ASCO guidance allows pemetrexed/platinum chemotherapy to be incorporated into perioperative treatment for appropriately selected surgical patients.

Immunotherapy

Immunotherapy has significantly changed systemic treatment of pleural mesothelioma. For patients who require first-line systemic therapy, current treatment options can include immune-checkpoint blockade depending on histology, resectability, medical history, contraindications, and treatment goals.

Nivolumab Plus Ipilimumab — Nivolumab combined with ipilimumab is an established first-line systemic treatment option for newly diagnosed pleural mesothelioma and has an FDA indication for unresectable malignant pleural mesothelioma. The benefit of immunotherapy is particularly important in nonepithelioid disease, although treatment selection should be individualized.

Pembrolizumab Plus Platinum-Pemetrexed — For adults with unresectable advanced or metastatic malignant pleural mesothelioma, pembrolizumab combined with pemetrexed and platinum chemotherapy is an FDA-approved first-line treatment option. The FDA approved this combination in September 2024. For a patient with Stage 1 disease, systemic treatment decisions depend on the specific clinical situation rather than stage number alone.

Is Immunotherapy Used Before Surgery? This is an evolving area. Current ASCO guidance states that neoadjuvant immunotherapy-based treatment may be offered as an option in surgical candidates, though the strength of evidence is lower than for established systemic treatment in unresectable disease. This is different from saying that every Stage 1 surgical candidate should receive immunotherapy before surgery. An experienced multidisciplinary team should determine the appropriate sequencing of treatments.

Radiation Therapy

Radiation therapy can play a role in selected pleural mesothelioma treatment strategies, but its use is highly individualized. Potential roles can include selected multimodality treatment, local tumor control, treatment of specific sites, and palliation of pain or other symptoms. Radiation treatment of the pleura can be technically challenging because of the proximity of the lungs, heart, esophagus, spinal cord, and other structures, and should therefore be planned by a radiation oncology team experienced with thoracic malignancies when possible.

Multidisciplinary Treatment

A multidisciplinary team should ideally evaluate Stage 1 pleural mesothelioma. That team can include thoracic surgery, medical oncology, radiation oncology, pulmonology, thoracic radiology, thoracic pathology, palliative medicine, and specialized nursing and supportive-care professionals. The purpose of multidisciplinary review is not solely to recommend additional treatment — it is to identify the treatment strategy most appropriate for the individual patient.

Stage 1 Mesothelioma Prognosis

Stage is an important prognostic factor, and Stage 1 generally represents a more favorable anatomical situation than later-stage pleural mesothelioma. However, stage should not be used alone to predict a person’s outcome.

Other important factors include epithelioid versus biphasic or sarcomatoid histology, tumor biology, age, performance status, cardiopulmonary health, lymph-node status, whether surgery is appropriate, completeness of cytoreduction when performed, response to systemic therapy, laboratory findings, and other medical conditions. Consequently, individuals with the same Stage 1 classification may experience markedly different clinical courses. Our prognosis guide discusses these factors across all stages.

Stage 1 Mesothelioma Life Expectancy

There is no single medically reliable life-expectancy number that applies to every person with Stage 1 mesothelioma. Numbers reported online can be misleading because studies may involve different AJCC staging editions, definitions of Stage 1, treatment eras, surgical techniques, histologic subtypes, patient-selection criteria, institutions, and follow-up periods. A study based on an older Stage IA/IB system should not automatically be interpreted as describing AJCC Version 9 Stage I. Population-level statistics cannot predict individual patient outcomes.

SEER Survival Statistics Are Not AJCC Stage 1 Statistics

Another common source of confusion involves SEER survival data. SEER often groups cancer as localized, regional, or distant. These categories are useful for population-level statistics; however, SEER “localized” disease is not the same classification as AJCC Stage I. SEER categories should therefore not simply be relabeled as Stage 1, Stage 2, Stage 3, and Stage 4 survival statistics. This distinction is essential for the accurate presentation of prognostic information.

Can Stage 1 Mesothelioma Be Cured?

Stage 1 provides an opportunity to consider aggressive treatment in appropriately selected patients, but mesothelioma remains a difficult cancer to cure. The disease often grows diffusely along pleural surfaces, and microscopic tumor can remain even after extensive surgery. For this reason, treatment is generally discussed in terms of maximal disease control, prolonging survival when possible, delaying recurrence or progression, preserving function, controlling symptoms, and maintaining quality of life. Some carefully selected patients may achieve prolonged disease control following multimodality treatment; however, no treatment should be described as guaranteeing a cure.

Can Stage 1 Mesothelioma Come Back?

Yes. Recurrence can occur even after apparently complete macroscopic tumor removal. Possible recurrence patterns can include local or regional disease and, over time, distant progression. This underscores the importance of ongoing follow-up after treatment. The treating team determines surveillance based on the treatment received, clinical status, imaging findings, and institutional protocol.

Is Stage 1 Mesothelioma Terminal?

A Stage 1 diagnosis should not automatically be described as “terminal.” It is a serious cancer diagnosis, but Stage 1 represents nonmetastatic disease without identified regional lymph-node involvement under the current staging system. Some patients are eligible for active multimodality treatment. Therapeutic goals and expected prognosis should be discussed on an individual basis rather than inferred solely from the diagnosis of “mesothelioma.”

Why a Mesothelioma Specialist Matters

Pleural mesothelioma is rare. Diagnosis, staging, pathology interpretation, and treatment selection can therefore benefit from experience with this specific disease.

A specialist evaluation can be particularly useful when deciding whether Stage 1 has been assigned accurately, whether pathology should be reviewed, whether lymph-node staging is sufficient, whether surgery is appropriate, which surgical approach should be considered, whether systemic therapy should be given before or after surgery, and whether a clinical trial is appropriate.

Seeking another opinion does not necessarily mean the original treatment recommendation was wrong. For rare cancers, obtaining a specialist opinion can provide additional assurance before making major treatment decisions. Our find a specialist guide can help with that search.

Clinical Trials for Stage 1 Mesothelioma

Clinical trials are not limited to Stage 4 disease. Studies in earlier-stage pleural mesothelioma may investigate perioperative systemic therapy, immunotherapy before surgery, new combinations of systemic treatments, biomarkers, improved surgical strategies, radiation techniques, and methods of predicting recurrence.

Eligibility depends on the specific trial protocol. Patients interested in clinical trials are encouraged to consult with a mesothelioma treatment team prior to initiating therapy, when feasible.

What to Do After a Stage 1 Diagnosis

A Stage 1 diagnosis can involve complex decisions despite being the earliest formal stage. Useful questions for the treating team include:

1. Is my diagnosis definitely diffuse pleural mesothelioma?
2. Is my stage based on AJCC Version 9?
3. What are my exact T, N, and M categories?
4. What are my Psum and Fmax measurements?
5. Has my pathology been reviewed by a pathologist experienced in mesothelioma?
6. What is my histologic subtype?
7. Has regional lymph-node involvement been adequately assessed?
8. Is my disease considered technically resectable?
9. Am I an appropriate candidate for surgical cytoreduction?
10. Which surgical approach would be considered and why?
11. What are the expected benefits and risks of surgery in my specific case?
12. Should systemic treatment be given before or after surgery?
13. Are there reasons to choose chemotherapy, immunotherapy, or another strategy?
14. Should I obtain a second opinion at a high-volume mesothelioma center?
15. Are there clinical trials for which I may qualify?
16. What is the goal of treatment in my case?
17. How will treatment affect breathing, function, and quality of life?
18. What follow-up will be needed after treatment?

Frequently Asked Questions

What is Stage 1 mesothelioma?

Stage 1 pleural mesothelioma is the earliest stage in the current AJCC Version 9 system. It is defined as T1 N0 M0: the tumor meets T1 criteria, no regional lymph-node spread has been identified, and there is no distant metastasis.

Is Stage 1 mesothelioma divided into Stage 1A and Stage 1B?

Not under the current AJCC Version 9 system. Stage IA and IB terminology may appear in information based on older staging editions. Current Stage I is T1 N0 M0.

What does T1 mean in Stage 1 mesothelioma?

For clinical staging, T1 means the tumor is limited to the ipsilateral pleura, with Psum ≤12 mm and no qualifying fissural involvement, Fmax ≤5 mm.

Has Stage 1 mesothelioma spread to lymph nodes?

No regional lymph-node involvement is identified in Stage 1. Its nodal category is N0.

Has Stage 1 mesothelioma metastasized?

No. Stage 1 is M0, meaning distant metastasis has not been identified.

Can Stage 1 mesothelioma be surgically removed?

Some patients with Stage 1 disease may be candidates for surgical cytoreduction, but Stage 1 alone does not establish that surgery is appropriate. Histology, cardiopulmonary fitness, tumor anatomy, overall health, and multidisciplinary assessment are important.

Is surgery automatically recommended for Stage 1 mesothelioma?

No. Current ASCO guidance states that surgical cytoreduction should not be offered routinely based only on anatomical resectability. It is intended for highly selected patients with favorable characteristics after comprehensive staging.

Which histology is most favorable for surgery?

Current ASCO guidance particularly identifies epithelioid tumors with clinical T1–T3 N0 disease among favorable characteristics for consideration of maximal surgical cytoreduction.

Can sarcomatoid Stage 1 mesothelioma be treated with surgery?

Histology substantially affects treatment planning. Current ASCO guidance recommends against maximal surgical cytoreduction for histologically confirmed sarcomatoid mesothelioma.

Does Stage 1 mesothelioma require chemotherapy?

Not every patient follows the same treatment sequence. Systemic therapy can be incorporated into multimodality treatment depending on surgical candidacy, histology, treatment strategy, comorbidities, and patient preferences.

Can immunotherapy be used for mesothelioma?

Yes. Immunotherapy is an established component of modern pleural mesothelioma treatment. Its role in an individual Stage 1 patient depends on whether systemic treatment is indicated and on the overall treatment strategy.

Is Stage 1 mesothelioma curable?

Stage 1 provides greater opportunity for aggressive treatment than more advanced disease, but mesothelioma remains difficult to cure and recurrence can occur even after extensive treatment. Treatment goals should be discussed individually.

What is the survival rate for Stage 1 mesothelioma?

There is no single Version 9 Stage 1 survival percentage that accurately predicts an individual’s outcome. Many published studies use older staging editions or different patient populations, and SEER localized survival statistics are not equivalent to AJCC Stage I.

Should I get a second opinion?

A second opinion can be particularly useful in a rare cancer such as mesothelioma, especially before major surgery or when there is uncertainty about pathology, staging, resectability, or treatment sequencing.

Medical References

1. American Joint Committee on Cancer. Diffuse Pleural Mesothelioma. AJCC Cancer Staging System, Version 9. American College of Surgeons; 2024.
2. American Cancer Society. Stages of Mesothelioma. Last revised February 3, 2026.
3. International Association for the Study of Lung Cancer. Pleural Mesothelioma TNM Definitions — 9th Edition.
4. Kindler HL, et al. Treatment of Pleural Mesothelioma: ASCO Guideline Update. Journal of Clinical Oncology. 2025;43:1006–1038. doi:10.1200/JCO-24-02425.
5. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: Mesothelioma: Pleural. Version 2.2026.
6. National Cancer Institute. Mesothelioma Treatment. Updated May 16, 2025.
7. U.S. Food and Drug Administration. FDA Approves Pembrolizumab With Chemotherapy for Unresectable Advanced or Metastatic Malignant Pleural Mesothelioma. September 17, 2024.
8. U.S. Food and Drug Administration. Nivolumab plus ipilimumab prescribing information for unresectable malignant pleural mesothelioma.

Editorial and Medical Review Information